Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Brugge – page 17

1 245 clinical trials in Brugge, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Brugge at a glance
1 245
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 245 trials in Brugge

Open in trial search

Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Syndax Pharmaceuticals Inc.

Iron deficiency+1

Recruiting

A Study of Ferric Carboxymaltose to Improve Exercise Ability in Patients with Pulmonary Hypertension and Iron Deficiency

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Ziekenhuis Oost Limburg

Ovarian cancer

Recruiting

A Study of Mirvetuximab Soravtansine, Carboplatin, and Bevacizumab in Adults with Ovarian Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

A Study of Sacituzumab Tirumotecan, Pembrolizumab, and Bevacizumab for Patients with Metastatic Cervical Cancer That Has Spread or Returned

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

HIV infection

Recruiting

A study testing VH4524184 with emtricitabine and tenofovir alafenamide compared to dolutegravir and lamivudine in adults with HIV-1 who have not received treatment before

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dolutegravir Sodium
  • Sponsor:Viiv Healthcare UK Limited

A Study of Acoramidis in Adult Patients with Transthyretin Amyloidosis with Cardiomyopathy Who Previously Received Tafamidis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acoramidis
  • Sponsor:Bayer Consumer Care AG

A Study Comparing BGB-16673 to Pirtobrutinib for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Has Returned or Not Responded

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BGB-16673
  • Sponsor:BeOne Medicines AG

A Study of BMS-986504 Combined with Nab-Paclitaxel and Gemcitabine for Patients with Untreated Metastatic Pancreatic Cancer with MTAP Gene Deletion

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Testing Stem Cell Transplant Methods and Medications Including Ruxolitinib and Blinatumomab for Children and Young Adults with Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Ospedale Pediatrico Bambino Gesu

A Study of JNJ-78278343 Compared to Placebo for Patients with Advanced Prostate Cancer That No Longer Responds to Hormone Treatment

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:JNJ-78278343
  • Sponsor:Janssen Cilag International

A Study of Amivantamab and Lazertinib for Adults with EGFR-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

A Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Brugge

What the registry says about research in the country

01 Bacterial Infections and Mycoses

Researchers in Brugge are advancing prevention and treatment of bacterial infections and fungal diseases through vaccine and antimicrobial studies.

  • Pneumococcal conjugate vaccine efficacy in infants
  • New antimicrobial agents for resistant bacterial strains
  • Diagnostic tools for invasive fungal infections
  • Safety assessment of novel antifungal prophylaxis

These trials aim to strengthen protection against serious infections and support public health in the region.

02 Cardiovascular Diseases

Investigators are testing innovative therapies to lower heart risk in patients with atherosclerosis, elevated lipoprotein(a), and amyloid‑related cardiomyopathy.

  • GLP‑1 analogue for ASCVD outcomes
  • Lipoprotein(a)‑lowering agent pelacarsen
  • RNA‑based therapy NTLA‑2001 for ATTR cardiomyopathy
  • Muvalaplin to reduce major cardiovascular events

The goal is to reduce morbidity and mortality from heart disease, a leading health concern in Brugge.

03 Digestive System Diseases

Studies target gastrointestinal disorders, evaluating novel compounds for irritable bowel syndrome relief and ulcerative colitis remission.

  • Comparative trial of ebastine vs mebeverine for IBS
  • Obefazimod for endoscopic improvement in ulcerative colitis
  • Long‑term safety of ABX464 in ulcerative colitis
  • Patient‑reported outcomes for bowel symptom management

Advances aim to enhance quality of life for individuals living with chronic digestive conditions.

04 Hemic and Lymphatic Diseases

A range of trials on hematologic malignancies are underway, seeking more effective regimens for lymphomas and acute leukemias.

  • Epcoritamab added to R‑mini‑CHOP for DLBCL
  • Lacutamab combined with GemOx in peripheral T‑cell lymphoma
  • Ziftomenib plus standard chemotherapy for NPM1‑mutated AML
  • Targeted therapy for KMT2A‑rearranged AML

These efforts aim to improve survival and reduce treatment toxicity for patients with blood cancers in the city.

05 Immune System Diseases

Research includes autoimmune and immune‑mediated conditions, testing agents that restore immune balance such as in chronic graft‑versus‑host disease and Graves’ disease.

  • Belumosudil versus best available therapy for chronic GVHD
  • IMVT‑1402 for maintaining euthyroidism in Graves’ disease
  • Immunogenicity study of PCV21 versus 15vPCV in infants
  • Novel immunomodulators for rare immune disorders

Outcomes may provide new options for patients whose immune systems attack their own tissues.

06 Male Urogenital Diseases

Trials focus on advanced prostate cancer, comparing targeted agents with standard chemotherapy to extend survival in metastatic castration‑resistant prostate cancer.

  • BNT324 versus docetaxel in mCRPC
  • Pasritamig combined with best supportive care for late‑line mCRPC
  • Biomarker‑driven therapy for hormone‑refractory prostate tumors
  • Quality‑of‑life assessments in prostate cancer treatment

The aim is to offer men in Brugge more effective therapeutic choices when disease progresses.

07 Neoplasms

Broad oncology programs explore innovative treatments for ovarian cancer and other gynecologic malignancies, including fallopian tube and peritoneal tumors.

  • Sofetabart Mipitecan with/without bevacizumab for platinum‑resistant ovarian cancer
  • Combination strategies for platinum‑sensitive ovarian disease
  • Targeted maintenance therapies after surgery
  • Translational studies linking tumor genetics to response

These studies strive to improve response rates and long‑term outcomes for women affected by gynecologic malignancies in Brugge.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.